128 related articles for article (PubMed ID: 35760938)
21. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases.
Zheng YQ; Li HJ; Chen L; Lin SP
Sci Rep; 2022 Oct; 12(1):17955. PubMed ID: 36289319
[TBL] [Abstract][Full Text] [Related]
23. Humoral response to SARS-CoV-2 adenovirus vector vaccination (ChAdOx1 nCoV-19 [AZD1222]) in heart transplant recipients aged 18 to 70 years of age.
Tanner R; Starr N; Chan G; Dempsey E; Heffernan E; Newman E; O'Neill J; Hannan MM; Lynch B; Joyce E
J Heart Lung Transplant; 2022 Apr; 41(4):492-500. PubMed ID: 35090809
[TBL] [Abstract][Full Text] [Related]
24. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study.
Barin B; Kasap U; Selçuk F; Volkan E; Uluçkan Ö
Lancet Microbe; 2022 Apr; 3(4):e274-e283. PubMed ID: 35165669
[TBL] [Abstract][Full Text] [Related]
25. Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases.
Arumahandi de Silva AN; Frommert LM; Albach FN; Klotsche J; Scholz V; Jeworowski LM; Schwarz T; Ten Hagen A; Zernicke J; Corman VM; Drosten C; Burmester GR; Biesen R
Ann Rheum Dis; 2022 Jun; 81(6):881-888. PubMed ID: 35288376
[TBL] [Abstract][Full Text] [Related]
26. Antibody response to SARS-CoV-2 mRNA vaccines in patients with rheumatic diseases in Japan: Interim analysis of a multicentre cohort study.
Kashiwado Y; Kimoto Y; Sawabe T; Irino K; Nakano S; Hiura J; Wang Q; Kawano S; Ayano M; Mitoma H; Ono N; Arinobu Y; Niiro H; Hotta T; Kang D; Akashi K; Ohshima S; Takeuchi T; Horiuchi T
Mod Rheumatol; 2023 Mar; 33(2):367-372. PubMed ID: 35411376
[TBL] [Abstract][Full Text] [Related]
27. Humoral Response in Hemodialysis Patients Following COVID-19 Vaccination and Breakthrough Infections during Delta and Omicron Variant Predominance.
Chinnadurai R; Wu HHL; Cox E; Moore J; Clough T; Lamerton E; Donne R; O'Riordan E; Poulikakos D
Vaccines (Basel); 2022 Mar; 10(4):. PubMed ID: 35455248
[TBL] [Abstract][Full Text] [Related]
28. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity of COVID-19 vaccines in adult patients with autoimmune inflammatory rheumatic diseases: A systematic review and meta-analysis.
Al-Haideri M; Mohammad TAM; Darvishzadehdeldari S; Karbasi Z; Alimohammadi M; Faramarzi F; Khorasani S; Rasouli A; Tahmasebi S; Darvishi M; Akhavan-Sigari R
Int J Rheum Dis; 2023 Jul; 26(7):1227-1234. PubMed ID: 37309305
[TBL] [Abstract][Full Text] [Related]
30. Low SARS-CoV-2 infection rates and high vaccine-induced immunity among German healthcare workers at the end of the third wave of the COVID-19 pandemic.
Brehm TT; Thompson M; Ullrich F; Schwinge D; Addo MM; Spier A; Knobloch JK; Aepfelbacher M; Lohse AW; Lütgehetmann M; Schulze Zur Wiesch J
Int J Hyg Environ Health; 2021 Sep; 238():113851. PubMed ID: 34601375
[TBL] [Abstract][Full Text] [Related]
31. The immunogenicity of seasonal and pandemic influenza vaccination in autoimmune inflammatory rheumatic patients-a 6-month follow-up prospective study.
Lakota K; Perdan-Pirkmajer K; Sodin-Šemrl S; Čučnik S; Šubelj V; Prosenc K; Mrak Poljšak K; Tomšič M; Ambrožič A; Praprotnik S
Clin Rheumatol; 2019 May; 38(5):1277-1292. PubMed ID: 30761436
[TBL] [Abstract][Full Text] [Related]
32. Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine.
Kang YM; Minn D; Lim J; Lee KD; Jo DH; Choe KW; Kim MJ; Kim JM; Kim KN
J Korean Med Sci; 2021 Nov; 36(46):e311. PubMed ID: 34845875
[TBL] [Abstract][Full Text] [Related]
33. Immune-mediated necrotizing myopathy following vaccination with the AstraZeneca (AZD1222) COVID-19 vaccine: A case report and brief review.
Ansari B; Najafi MA; Kheradmand M; Najafi F; Najafi MR
Rev Neurol (Paris); 2023 Jun; 179(6):630-635. PubMed ID: 36754672
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.
Jara A; Undurraga EA; Zubizarreta JR; González C; Pizarro A; Acevedo J; Leo K; Paredes F; Bralic T; Vergara V; Mosso M; Leon F; Parot I; Leighton P; Suárez P; Rios JC; García-Escorza H; Araos R
Lancet Glob Health; 2022 Jun; 10(6):e798-e806. PubMed ID: 35472300
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study.
Furer V; Eviatar T; Zisman D; Peleg H; Paran D; Levartovsky D; Zisapel M; Elalouf O; Kaufman I; Meidan R; Broyde A; Polachek A; Wollman J; Litinsky I; Meridor K; Nochomovitz H; Silberman A; Rosenberg D; Feld J; Haddad A; Gazzit T; Elias M; Higazi N; Kharouf F; Shefer G; Sharon O; Pel S; Nevo S; Elkayam O
Ann Rheum Dis; 2021 Oct; 80(10):1330-1338. PubMed ID: 34127481
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial.
Asano M; Okada H; Itoh Y; Hirata H; Ishikawa K; Yoshida E; Matsui A; Kelly EJ; Shoemaker K; Olsson U; Vekemans J
Int J Infect Dis; 2022 Jan; 114():165-174. PubMed ID: 34688944
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity of Covishield vaccine in patients with autoimmune rheumatic diseases.
Gupta V; Gupta VK; Bajwa NK; Sachdeva A; Garg R; Ghosh A
J Family Med Prim Care; 2024 May; 13(5):1904-1910. PubMed ID: 38948615
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: a multi-centric hospital-based case-control study.
Bhatnagar T; Chaudhuri S; Ponnaiah M; Yadav PD; Sabarinathan R; Sahay RR; Ahmed F; Aswathy S; Bhardwaj P; Bilimale A; Kumar MS; Logaraj M; Narlawar U; Palanivel C; Patel P; Rai SK; Saxena V; Singh A; Thangaraj JW; Agarwal A; Alvi Y; Amoghashree ; Ashok P; Babu D; Bahurupi Y; Bhalavi S; Behera P; Biswas PP; Charan J; Chauhan NK; Chetak KB; Dar L; Das A; Deepashree R; Dhar M; Dhodapkar R; Dipu TS; Dudeja M; Dudhmal M; Gadepalli R; Garg MK; Gayathri AV; Goel AD; Gowdappa HB; Guleria R; Gupta MK; Islam F; Jain M; Jain V; Jawahar MLS; Joshi R; Kant S; Kar SS; Kalita D; Khapre M; Khichar S; Kombade SP; Kohli S; Kumar A; Kumar A; Kumar D; Kulirankal KG; Leela KV; Majumdar T; Mishra B; Misra P; Misra S; Mohapatra PR; Murthy MN; Nyayanit DA; Patel M; Pathania M; Patil S; Patro BK; Jalandra R; Rathod P; Shah N; Shete A; Shukla D; Shwethashree M; Sinha S; Sumana MN; Surana A; Trikha A; Tejashree A; Venkateshan M; Vijaykrishnan G; Wadhava S; Wig N; Gupta N; Abraham P; Murhekar MV
Int J Infect Dis; 2022 Sep; 122():693-702. PubMed ID: 35843496
[TBL] [Abstract][Full Text] [Related]
39. Inflammatory rheumatic diseases developed after COVID-19 vaccination: presentation of a case series and review of the literature.
Akkuzu G; Bes C; Özgür DS; Karaalioğlu B; Mutlu MY; Yıldırım F; Atagündüz P; Gündüz A; Soy M
Eur Rev Med Pharmacol Sci; 2023 Mar; 27(5):2143-2151. PubMed ID: 36930514
[TBL] [Abstract][Full Text] [Related]
40. Humoral antibody response to the first dose of the ChAdOx1 nCoV-19 vaccine in Asian patients undergoing hemodialysis.
Tung KT; Peng YS; Hsu SP; Wu HY; Chiu YL; Yang JY; Pai MF; Shu KH; Pan SY; Lu HM; Lin WY; Liao CH; Chu FY; Tsai WC
Hemodial Int; 2022 Jul; 26(3):369-376. PubMed ID: 35411681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
